To stimulate anti-tumor immunity and reproduce this immune phenotype in neuroblastoma tumors, we used CRISPR-Cas9 to knockout MLH1—a crucial molecule in the DNA mismatch repair pathway—to induce mismatch repair deficiency in a poorly immunogenic murine neuroblastoma model. The gene discussed is MLH1; the disease is neuroblastoma.